R
Royalty Pharma plc D
D
RPRX
34.845
USD
-0.42
(-1.18%)
مغلق
حجم التداول
126,787
الربح لكل سهم
3
العائد الربحي
2.53
P/E
14
حجم السوق
14,682,660,543
الأخبار المقالات
العنوان: Royalty Pharma plc
القطاع: Healthcare
الصناعة: Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.